Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

被引：0
|
作者：
Eder, Lihi [1 ,2 ]
Gladman, Dafna [3 ]
Aydin, Sibel [4 ]
Ogdie, Alexis [5 ]
Shi, Harry [6 ]
Landry, Pierre-Alexandre [7 ]
Luna, Rayana [7 ]
机构：
[1] Womens Coll Res Inst, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Toronto, Krembil Res Inst, Dept Med, Toronto Western Hosp, Toronto, ON, Canada
[4] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada
[5] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[6] Pfizer Inc, Collegeville, PA USA
[7] Pfizer Canada ULC, Kirkland, WA USA
来源：
JOURNAL OF RHEUMATOLOGY | 2020年 / 47卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
10
引用
收藏
页码：1043 / 1044
页数：2
相关论文
共 50 条
  • [31] Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
    Philip J. Mease
    Ana-Maria Orbai
    Oliver FitzGerald
    Mohamed Bedaiwi
    Rajiv Dona L. Fleishaker
    Pamela Mundayat
    Philip S. Young
    [J]. Arthritis Research & Therapy, 25
  • [32] Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
    Mease, Philip J.
    Orbai, Ana-Maria
    FitzGerald, Oliver
    Bedaiwi, Mohamed
    Fleishaker, Dona L.
    Mundayat, Rajiv
    Young, Pamela S.
    Helliwell, Philip
    [J]. ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [33] Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
    Felten, Renaud
    Widawski, Laura
    Spielman, Lionel
    Gottenberg, Jacques-Eric
    Duret, Pierre-Marie
    Rampakakis, Emmanouil
    Sharaf, Mohamed
    Constantin, Caren
    Campana, Vincenza
    Messer, Laurent
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4429 - 4432
  • [34] IMPACT OF RACE ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, 3 AND 3B/4 CLINICAL TRIALS
    Wright, G. C.
    Mysler, E.
    Chen, Y. H.
    Kinch, C.
    Yndestad, A.
    Kwok, K.
    Cadatal, M. J.
    Germino, R.
    Ogdie, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 609 - 609
  • [35] Lasmiditan in Patients with Common Migraine Comorbidities: A Post hoc, Safety, and Efficacy Analysis of Two Phase 3 Randomized Clinical Trials
    Clemow, David
    Baygani, Simin
    Hauck, Paula
    Hultman, Cory
    [J]. NEUROLOGY, 2020, 94 (15)
  • [36] Lasmiditan in Patients with Common Migraine Comorbidities: A Post hoc, Safety, and Efficacy Analysis of Two Phase 3 Randomized Clinical Trials
    Clemow, D. B.
    Baygani, S. K.
    Hauck, P. M.
    Hultman, C. B.
    Wilhelm, S.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 1094 - 1094
  • [37] Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials
    Dai, Qianqian
    Zhang, Yanfeng
    Liu, Qian
    Zhang, Chijin
    [J]. CLINICAL RHEUMATOLOGY, 2024, 43 (05) : 1605 - 1613
  • [38] Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials
    Qianqian Dai
    Yanfeng Zhang
    Qian Liu
    Chijin Zhang
    [J]. Clinical Rheumatology, 2024, 43 : 1605 - 1613
  • [39] Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
    Lee, Y. H.
    Song, G. G.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (06): : 590 - 603
  • [40] Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
    Lee, Young Ho
    Song, Gwan Gyu
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2020, 23 (07) : 868 - 875
12345